Today
-0.25%
5 Days
+0.30%
1 Month
+0.29%
6 Months
+25.31%
Year to Date
+51.09%
1 Year
+95.02%
• Stryker exceeded second-quarter earnings expectations across MedSurg and Neurotechnology segments. • Management raised full-year earnings guidance citing operational efficiencies and market share gains. • Analysts maintain a Buy rating with an average price target of $385.60.
• Quarterly procedure volume growth exceeded expectations, driving the company’s recent valuation increase. • Adoption of robotic platforms and AI integration supports recurring revenue and surgical precision. • Intuitive Surgical reports $10.06 billion in annual revenue with high institutional investor support.


| Shareholders | Proportion |
|---|---|
| BlackRock Institutional Trust Company, N.A. | 11.07% |
| Janus Henderson Investors | 8.77% |
| Farallon Capital Management, L.L.C. | 8.34% |
| Vanguard Portfolio Management, LLC | 4.88% |
| Shareholder Types | Proportion |
|---|---|
| Investment Advisor | 50.16% |
| Investment Advisor/Hedge Fund | 35.35% |
| Hedge Fund | 15.37% |
| Research Firm | 4.24% |
Related Instruments